Orthobiological Therapies in Musculoskeletal Disorders
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorPROREGEN
About this trial
To evaluate the clinical and functional effects of using orthobiological therapies (hyaluronic acid, platelet-rich plasma, bone marrow aspirate, nanofat, among others) in the treatment of various musculoskeletal diseases in patients routinely treated at the Proregen Medical Clinic and its affiliates.
The sample will consist of adult patients (≥18 years), of both sexes, with different musculoskeletal diagnoses involving joints, tendons, ligaments, cartilage or bone, among others.
Eligibility criteria
Qualifiers
Age 18 or older;
Clinical and/or radiological diagnosis of an eligible musculoskeletal condition;
Formal clinical indication for treatment with orthobiological agents, according to routine care;
Regular access to the WhatsApp application, ensuring the necessary communication for sending and receiving digital questionnaires and other study instructions;
Disqualifiers
Medical contraindication to the use of orthobiologics (e.g., active infection, severe hematological diseases, active cancer);
Recent use (≤3 months) of orthobiologic therapies in the same area to be treated;
Pregnant or breastfeeding women;
Cognitive or psychiatric diseases that prevent adequate clinical follow-up;
Trial design
Treatments tested in this trial
- PRP injection
- Bone Marrow Concentrate (BMAC)
- Hyaluronic Acid (Viscosupplementation)
- Nanofat
Treatment groups
300 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
PROREGEN
Lead sponsor
Centro Universitário Univates
Collaborator
Source ClinicalTrials.gov